Work at Shouyao Holdings (Beijing) Co. Ltd. has led to the identification of new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.
Cimplrx Co. Ltd. and Dong Wha Pharmaceutical Co. Ltd. have discovered new carboxamide derivatives acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) and/or IRAK-1 inhibitors. As such, they are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Genesis Molecular AI Inc. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) (mutant) inhibitors potentially useful for the treatment of cancer.
Tyra Biosciences Inc. has patented new pyrazolopyridine and imidazopyridine derivatives acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
Shanghai Henlius Biologics Co. Ltd., Shanghai Henlius Biopharmaceutical Co. Ltd. and Shanghai Henlius Biotech Inc. have disclosed new antibody-drug conjugates comprising a monoclonal antibody targeting HER2 covalently linked to a camptothecin derivative potentially useful for the treatment of cancer.
Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has prepared and tested new bispecific antibody-drug conjugates (ADCs) consisting of a bispecific antibody or antigen-binding fragments targeting B7 homolog 3 (B7-H3; CD276) and delta-like protein 3 (DLL3) linked to cytotoxic drug; they are described as potentially useful for the treatment of cancer.
Alphina Therapeutics Inc. has identified new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors potentially useful for the treatment of autoimmune and metabolic diseases, inflammatory disorders and cancer.
RSS